Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01548430 | A Safety Study of TTP4000 in Subjects With Alzheimer's Disease | PHASE1 | COMPLETED | 8 | — | — | Oct 1, 2011 | Feb 1, 2013 | Feb 12, 2015 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| TTP4000 1.0 mg/kg | EXPERIMENTAL | Administered subcutaneously |
| TTP4000 3.0 mg/kg | EXPERIMENTAL | Administered subcutaneously |
| Placebo | PLACEBO_COMPARATOR | Administered subcutaneously |
| Name | Type | Description |
|---|---|---|
| TTP4000 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Males or females ≥ 50 years of age. * Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive. * Weight ≥ 50 kg. * Alzheimer's disease according to the DSM-IV-TR criteria and a score between 20 and 26 on the Mini Mental State Exam. * Subject must have a medical history for at least...